NCT04649073 - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 18, 2021

Primary Completion Date

April 9, 2025

Study Completion Date

January 31, 2041

Conditions

Multiple Myeloma (MM)

Interventions

BIOLOGICAL

OPC-415

OPC-415 (up to 1×10\^7cells/kg) On 2 days

Trial Locations (8)

Tokai University Hospital, Isehara-shi

Nagoya City University Hospital, Nagoya

National Hospital Organization Okayama Medical Center, Okayama

Sapporo Medical University Hospital, Sapporo

Tohoku University Hospital, Sendai

Japanese Red Cross Medical Center, Shibuya-ku

Osaka University Hospital, Suita-shi

Yamagata University Hospital, Yamagata